Difficulty: Medium
Average Score: 77%
Practice
A 12-year-old patient with localized osteosarcoma is being treated with cisplatin, doxorubicin, and high-dose methotrexate. The pain at his primary site rapidly resolves after initiation of chemotherapy. After tumor resection, pathology reveals the tumor was greater than 95% necrotic. You want to continue cisplatin, doxorubicin, and high-dose methotrexate. Which of the following is the best answer regarding the evaluations that should be performed to monitor for toxicity in patients receiving cisplatin, doxorubicin, and high-dose methotrexate?
Correct answer
C
Rationale
Cisplatin is associated with high-frequency hearing loss, which can be symptomatic with tinnitus and requires periodic monitoring with audiogram. Cisplatin also causes decreases in glomerular filtration rate and cation wasting frequently resulting in hypomagnesemia. Although hypomagnesemia can predispose a patient to prolonged QTc, that is a secondary effect. Doxorubicin causes myelosuppression as well as a late effect of decreased left ventricular ejection fraction measured by echocardiogram. High-dose methotrexate is contraindicated in patients with significant acute or chronic kidney disease. Elevated serum creatinine should prompt further evaluation of renal function prior to administration of high-dose methotrexate.